Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00172172 · ClinicalTrials.gov registry record · Phase 3
Calcium Supplementation in Postmenopausal Women
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 374
- Enrollment target
NCT00172172 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 374 participants.
The verdict
NCT00172172, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 374 participants
- Enrollment target
Study Summary
This study is evaluating the effects of calcium supplementation on the efficacy and safety of recombinant parathyroid hormone (ALX1-11) in postmenopausal women with osteoporosis. The primary objective of this clinical study is to evaluate whether increases in bone mineral density (BMD) for subjects treated with ALX1-11 and receiving no calcium supplementation are less than increases in BMD observed for subjects treated with ALX1-11 and receiving calcium supplementation.
Interventions
- DRUG placebo
- DRUG PTH/Calcium
- DRUG PTH/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2004-01-10 |
| Est. Completion | 2005-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00172172
The ClinicalTrials.gov registry entry for NCT00172172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 374 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00172172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00172172 about?
NCT00172172 is a clinical study titled "Calcium Supplementation in Postmenopausal Women". This study is evaluating the effects of calcium supplementation on the efficacy and safety of recombinant parathyroid hormone (ALX1-11) in postmenopausal women with osteoporosis. The primary objective of this clinical study is to evaluate whether increases in bone mineral density (BMD) for subjects ...
What is the current status of trial NCT00172172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 374 participants. The study started on 2004-01-10. Estimated completion is 2005-03-11.
What interventions are being tested in trial NCT00172172?
The interventions under investigation include: placebo (DRUG), PTH/Calcium (DRUG), PTH/placebo (DRUG).
Who is sponsoring clinical trial NCT00172172?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.